In this episode of Executive Insights for Life Sciences Innovators, Don Alexander speaks with Dr. Anil Goyal, Co-Founder and CEO of IMMvention Therapeutix, a VC-backed biotechnology company developing globally accessible therapies for rare and chronic diseases, including sickle cell disease and Friedreich’s ataxia.

Anil shares insights from nearly 30 years in biotechnology leadership spanning company formation, fundraising, strategic partnerships, and therapeutic innovation across multiple modalities and disease areas. The conversation explores Immvention’s scientific approach, the realities of building emerging biotech companies in today’s funding environment, and the balance between scientific ambition and operational discipline.

They also discuss Immvention’s strategic collaboration with Novo Nordisk focused on developing oral therapies for sickle cell disease and other chronic diseases, including what partnerships like these can signal about platform validation and long-term development strategy.

Beyond his work in biotechnology, Anil is also a passionate ecosystem builder and co-founder of the OpenDoors Group, a nonprofit organization focused on increasing equity, diversity, and access for the next generation of life sciences entrepreneurs and innovators. The discussion also touches on North Carolina’s growing R&D ecosystem and the importance of regional innovation clusters in advancing life sciences.

This episode was streamed live on YouTube on May 18, 2026. Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠genecoda.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠.